MARQUEE_2B | R Documentation |
Kaplan-Meier digitized data from MARQUEE, figure 2B (PMID 26169611). A reported sample size of 1,048 for a primary endpoint of OS in lung cancer.
MARQUEE_2B
A data frame of 1,048 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (erlotinib_placebo, erlotinib_tivantinib) | |
Scagliotti G, von Pawel J, Novello S, et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2667–74.
summary(MARQUEE_2B)
kmplot(MARQUEE_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.